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Abstract
Background
Human papillomavirus (HPV) is a common sexually transmitted infection that is implicated
in 99.7% of cervical cancers and several other cancers that affect both men and women.
Despite the role that HPV plays in an estimated 5% of all cancers and the evolving role of
HPV vaccination and testing in protecting the public against these cancers, preliminary
research in New Zealand health professionals suggest knowledge about HPV may not be
sufficient.
Methods
A total of 230 practice nurses, smear takers and other clinical and laboratory staff who
attended a range of training events completed a cross-sectional survey between April 2016
and July 2017. The survey explored four broad areas: demographics and level of experi-
ence, HPV knowledge (general HPV knowledge, HPV triage and test of cure (TOC) knowl-
edge and HPV vaccine knowledge), attitudes towards the HPV vaccine and self-perceived
adequacy of HPV knowledge.
Results
The mean score on the general HPV knowledge questions was 13.2 out of 15, with only
25.2% of respondents scoring 100%. In response to an additional question, 12.7% thought
(or were unsure) that HPV causes HIV/AIDS. The mean score on the HPV Triage and TOC
knowledge questions was 7.4 out of 10, with only 9.1% scoring 100%. The mean score on
the HPV vaccine knowledge questions was 6.0 out of 7 and 44.3% scored 100%. Only
63.7% of respondents agreed or strongly agreed that they were adequately informed about
HPV, although 73.3% agreed or strongly agreed that they could confidently answer HPV-
related questions asked by patients. Multivariate analyses revealed that knowledge in each
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domain predicted confidence in responding to patient questions. Furthermore, the number
of years since training predicted both HPV knowledge and Triage and TOC knowledge.
Discussion
Although overall level of knowledge was adequate, there were significant gaps in knowl-
edge, particularly about the role of HPV testing in the New Zealand National Cervical
Screening Programme. More education is required to ensure that misinformation and stigma
do not inadvertently result from interactions between health professionals and the public.
Introduction
Human papillomavirus (HPV) is responsible for 99.7% of cases of cervical cancer along with
some head and neck, penile and anal cancers. There are approximately 150 new diagnoses and
50 deaths from cervical cancer in New Zealand (NZ) every year [1], while head and neck can-
cers attributable to HPV are increasing in both men and women with 94 new cases and 43
deaths estimated for 2012 [2]. In addition, there are longstanding ethnic inequalities in cervical
cancer incidence and mortality, and cervical screening coverage remains low (and cancer inci-
dence and mortality high) for indigenous Māori women as well as Pacific women [3].
The NZ National Cervical Screening Programme (NCSP), which was established in 19904,
recommends 3-yearly routine screening with liquid-based cytology (LBC) for 20–69 year-old
women, with HPV triage testing for low grade (ASC-US/LSIL) cytology in women 30+ years.
The programme also recommends testing of cure following treatment for a high-grade lesion
[4]. From late 2018 the NCSP will introduce HPV testing as the primary screening test for
women aged 25–68 years on a 5 yearly basis [5].
To reduce infection with high-risk types of HPV and its related cancers, the NZ National
HPV Immunisation Programme was introduced in September 2008, offering free HPV vacci-
nation (Gardasil, Merck) for females born in 1990 or later. School-based immunisation for
12–13 year-old girls commenced in most regions in 2009 [1] and the three-dose coverage
achieved by the program in cohorts born in 1991–2002 reached approximately 48–66% nation-
wide [1]. In January 2017, the free programme was extended to boys and young men, the
upper age for free vaccination was increased to 26 years, a two-dose schedule was implemented
for individuals aged 14 and under, and the vaccine used was changed to nonavalent Gardasil 9
(Merck) [1].
Previous research has identified that health professionals can play an important role in vac-
cine uptake. In an Italian survey assessing childhood vaccine hesitancy in parents, hesitancy
was significantly more common in those parents who lacked confidence in their child’s doctor
[6]. In a US study, more adolescents had not had the HPV vaccine when their parents felt they
were not able to openly discuss their concerns with the doctor [7] and in a second US study of
parents who decline then later accept the HPV vaccination for their child, secondary accep-
tance was more likely in parents who received follow-up counselling from their child’s health-
care provider [8]. Furthermore, recent research in the UK has also identified that women who
report greater trust in their doctor were less likely to have decided not to undergo cervical
screening [9].
In NZ, a cervical sample taker is a registered health practitioner (nurse or doctor) who
holds a current practising certificate and has completed appropriate cervical screening train-
ing as part of a medical degree, midwifery training programme or via a New Zealand
HPV Knowledge in NZ clinicians
PLOS ONE | https://doi.org/10.1371/journal.pone.0197648 December 31, 2018 2 / 16
Qualifications Authority (NZQA) accredited course for cervical sample takers. Previous
research exploring the knowledge of GPs and practice nurses (PNs) in Christchurch, New
Zealand about HPV used 5 questions as part of a larger survey exploring attitudes towards
HPV vaccination [10]. Whilst performance across the 5 questions was reasonable, there was
uncertainty as indicated by the number of ‘not sure’ responses, as well as some variability
across questions. For example, while more than 90% of GPs and PNs knew that HPV vaccina-
tion would not eliminate the need for cervical screening, only 33% of GPs and 7% of PNs
knew that anogenital warts caused by HPV 6 and 11 are not a precursor to cervical cancer.
Only half of GPs and 42% of PNs knew that most HPV infections will clear without medical
treatment and a quarter of GPs and nearly a third of PNs did not know, or were unsure,
whether persistent HPV was a necessary cause of cervical cancer.
To our knowledge there are no studies exploring what primary care staff such as GPs, PNs
and smear takers in NZ know about HPV since 2009. In light of the recent changes to the
immunisation programme and the forthcoming changes to the NCSP, it is important to
benchmark what nurses and smear takers understand about HPV, whether they feel well
informed and assess any training needs they might identify.
Methods
Ethics approval was granted by the Massey University Ethics Committee 4000015595. The
project was registered with Waitemata DHB localities (Reference number RM13518). Both
Waitemata and Auckland DHB confirmed that locality authorisation was not required as the
research was carried out in community healthcare settings.
An anonymous cross-sectional survey was conducted between April 2016 and July 2017.
GPs, practice nurses, smear takers and other clinical and laboratory staff who attended a vari-
ety of training events (11 in total) in Auckland District Health Board (DHB), Hutt Valley DHB
and Waitemata DHB catchment areas were invited to complete the paper-based survey. The
sample represents the number of respondents we were able to collect within the one-year time
frame. Participants were provided with an information sheet to read prior to completing the
survey. The survey was taken from Patel et al., [11] who had incorporated most of the items
from Waller et al., [12] and was adapted by adding back in a question about HPV and HIV/
AIDS from Waller et al., and by changing some wording to make the terminology or protocols
New Zealand-specific.
We established the face validity of the adapted questionnaire for the NZ clinical environ-
ment by having two groups peer review the survey, firstly to ensure we had captured the scope
adequately and secondly to ensure questions were well structured. These groups included
members of the DHB Immunisation team and cervical screening specialist doctors as well as
nurse practitioners.
The final survey explored four broad categories: demographics and level of experience;
HPV knowledge (general HPV knowledge, HPV triage and test of cure (TOC) knowledge and
HPV vaccine knowledge), which were assessed using a true, false, don’t know format; and atti-
tudes towards the HPV vaccine and self-perceived adequacy of HPV knowledge, which were
assessed using 5-point Likert scales (the survey is publicly available here: osf.io/ub7g2, DOI 10.
17605/OSF.IO/UB7G2).
Statistical analyses
Demographic factors included age, profession and years since HPV training. For analyses, pro-
fession was collapsed into four categories (nurse; general practitioner (GP); colposcopy, which
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included colposcopists and colposcopy nurses; and laboratory staff and other), and years since
HPV training was collapsed into 3 categories (never;� 1 year; > 1 year).
Factors affecting HPV knowledge were assessed using ordinal regression analysis. The
approach for model development was to conduct univariate analyses initially and then enter
variables into the full multivariate models that showed a statistically significant (P<0.05) asso-
ciation with the main outcomes in the univariate analyses. The rationale for this was that if a
variable was associated with the main outcome measure, it could be a confounder.
Factors affecting self-perceived adequacy of HPV knowledge were also assessed. Feeling
adequately informed and feeling confident in answering patient questions were converted
from 5-point Likert scales to binary variables of yes (strongly agree, agree) and no or unde-
cided (strongly disagree, disagree or undecided) as the dependent variables.
Results
A total of 234 health professionals completed the survey. Due to the opportunistic nature of
participant recruitment, a response rate was not able to be calculated. The data for four indi-
viduals were removed, as there were large sections that had been left unanswered. A total of 22
health professionals had at least one answer missing for the general HPV knowledge questions,
18 had at least one answer missing for the Triage and TOC knowledge questions, and 8 health
professionals had at least one answer missing for the vaccine knowledge questions. Overall, 40
participants had at least one answer missing across all of the questions (several participants
had missing data in more than one of the three sections). Details about participant gender, age
categories, profession, smear taker status and date of most recent training, if any, are presented
in Table 1.
General HPV knowledge
Out of a maximum knowledge score of 15 (see individual questions in Table 2 and excluding
the question about HIV/AIDS), the mean score achieved by participants was 13.3 (standard
deviation (SD) 2.0) and the median score was 14 (range 0–15, interquartile range (IQR) 13–15),
with 27.9% (N = 58) achieving 100%. One individual did not answer any questions correctly.
The following questions were most often answered incorrectly: HPV usually doesn’t need
any treatment (35.9% answered incorrectly or weren’t sure); Having sex at an early age
increases the risk of getting HPV (26.2%); Most sexually active people will get HPV at some
point in their lives (24.7%). In addition, more than 10% of health professionals incorrectly
thought (or were not sure) that HPV cannot be passed on by genital skin-to-skin contact, that
HPV does not cause genital warts, that using condoms does not reduce the risk of getting HPV
and that HPV can be cured with antibiotics.
Following Waller et al., [12] the item about HIV/AIDS was analysed separately from the
rest of the questions. In total, 87.2% of respondents correctly identified that HPV does not
cause HIV/AIDS.
HPV Triage and TOC knowledge
Out of a maximum knowledge score of 10 (see individual questions in Table 2), the mean
score achieved by the participants was 7.4 (SD 2.0) and the median score was 8 (range 0–10,
IQR 6–9), with 9.9% (N = 21) achieving 100%. Three individuals had no correct answers.
The following questions were answered incorrectly most often: All cervical samples show-
ing mild cellular (ASC-US/LSIL) are tested for high-risk HPV (55.3% answered incorrectly or
were not sure); All cervical samples taken 6 to 12 months post-treatment can be tested for
high-risk HPV (54.9%); If high-risk HPV test is negative at 12 and 24 post treatment they will
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still require annual follow up for life (39.1%); If cytology and high-risk HPV test are negative
at 12 and 24 post treatment, they will require a repeat smear in 3 Years (24.4%). In addition,
more than 10% of health professionals incorrectly thought (or weren’t sure) that an HPV test
can tell how long a person has had an HPV infection; an HPV test cannot be done at the same
time as a Smear test; HPV testing is used to indicate if the HPV vaccine is needed; when an
HPV test has been done that the results are available the same day; If an HPV test shows that a
women does not have HPV her risk of cervical cancer is not low.
HPV vaccine knowledge
Out of a maximum knowledge score of 7 (see individual questions in Table 2), the mean score
achieved by the participants was 6.0 (SD 1.2) and the median score was 6 (range 0–7, IQR
5–7), with 45.9% (N = 102) achieving 100%. One individual had no answers correct.
Table 1. Participant characteristics.
Gender Gender N (%)
Female 212 (92.2)
Male 17 (7.4)
Not specified 1 (0.4)
Other 0 (0.0)
Age Age bracket N (%)
20–24 8 (3.5)
25–35 45 (19.7)
36–45 51 (22.3)
46–55 63 (27.5)
56–65 52 (22.7)
66–75 10 (4.4)
Blank1 1
Profession Profession N (%)
Registered nurse 150 (65.2)
Laboratory staff 25 (10.9)
General practitioner 12 (5.2)
Not disclosed 11 (4.8)
Colposcopist 2 (0.9)
Colposcopy nurse 2 (0.9)
Enrolled nurse 2 (0.9)
Other 26 (11.3)
Smear taking Smear taker status N (%)
Have taken a smear test2 123 (53.5)
Never taken a smear test 107 (46.5)
HPV training Date of last training N (%)
Never 99 (47.1)
last 6 months 16 (7.6)
7–12 months 30 (14.3)
13–24 months 35 (16.7)
>2yrs 30 (14.3)
Blank1 20
1Omitted from % calculations
2 For the 123 who had, the years of experience ranged from 0.1 to 42 years (mean 8.7 years, median 6.5 years).
https://doi.org/10.1371/journal.pone.0197648.t001
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Table 2. HPV and vaccine knowledge questions.
Correct
Response
N (%)
Incorrect
Response
N (%)
Answer “don’t
know”
N (%)
Missing
N1
General HPV knowledge questions
HPV can cause cervical cancer (TRUE) 228 (99.1) 1 (0.4) 1 (0.4) 0
Having many sexual partners increases the risk of getting HPV (TRUE) 223 (97.0) 5 (2.2) 2 (0.9) 0
HPV can be passed on during sexual intercourse (TRUE) 218 (96.0) 2 (0.9) 7 (3.1) 3
A person could have HPV for many years without knowing it (TRUE) 217 (96.9) 0 (0) 7 (3.1) 6
HPV always has visible signs or symptoms (FALSE) 216 (94.7) 5 (2.2) 7 (3.1) 2
HPV is very rare (FALSE) 215 (93.9) 7 (3.1) 7 (3.1) 1
There are many types of HPV (TRUE) 214 (93.0) 4 (1.7) 12 (5.2) 0
Men cannot get HPV (FALSE) 213 (92.6) 8 (3.5) 9 (3.9) 0
Using condoms reduces the risk of getting HPV (TRUE) 204 (89.5) 17 (7.5) 7 (3.1) 2
HPV can be passed on by genital skin-to-skin contact (TRUE) 203 (89.0) 9 (3.9) 16 (7.0) 2
HPV can cause genital warts (TRUE) 203 (89.0) 13 (5.7) 12 (5.3) 2
HPV can be cured with antibiotics (FALSE) 201 (87.8) 14 (6.1) 14 (6.1) 1
HPV can cause HIV/AIDS2 (FALSE) 198 (87.2) 13 (5.7) 16 (7.0) 3
Most sexually active people will get HPV at some point in their lives (TRUE) 171 (75.3) 29 (12.8) 27 (11.9) 3
Having sex at an early age increases the risk of getting HPV (TRUE) 169 (73.8) 44 (19.2) 16 (7.0) 1
HPV usually doesn’t need any treatment (TRUE) 147 (64.2) 67 (29.3) 15 (6.6) 1
HPV Triage and TOC knowledge questions
If a woman tests positive for HPV she will definitely get cervical cancer (FALSE) 220 (96.1) 5 (2.2) 4 (1.7) 1
An HPV test can be done at the same time as a Smear test (TRUE) 205 (89.5) 7 (3.1) 17 (7.4) 1
HPV testing is used to indicate if the HPV vaccine is needed (FALSE) 199 (87.3) 10 (4.4) 19 (7.9) 2
An HPV test can tell how long you have had an HPV infection (FALSE) 190 (83.0) 8 (3.5) 31 (13.5) 1
When you have an HPV test, you get the results the same day (FALSE) 189 (82.9) 8 (3.5) 31 (13.6) 2
If an HPV test shows that a woman does not have HPV her risk of cervical cancer is low (TRUE) 174 (76.0) 35 (15.3) 20 (8.7) 1
If cytology and high-risk HPV test are negative at 12 and 24 post treatment, they will need require a
repeat smear in 3 Years3 (TRUE)
171 (75.7) 25 (11.1) 30 (13.3) 4
If high-risk HPV test is negative at 12 and 24 post treatment they will still require annual follow up
for life3 (FALSE)
140 (60.9) 52 (22.6) 38 (16.5) 0
All cervical samples taken 6 to 12 months post-treatment can be tested for high-risk HPV3 (TRUE) 102 (45.1) 31 (13.7) 93 (41.2) 4
All cervical samples showing mild cellular (ASC-US/LSIL) are tested for high-risk HPV3 (FALSE) 101 (44.7) 85 (37.6) 40 (17.7) 4
HPV vaccine knowledge questions
The HPV vaccines offer protection against all sexually transmitted infections (FALSE) 218 (96.0) 3 (1.3) 6 (2.6) 3
Girls who have had the HPV vaccine do not need to have smear tests when they are older (FALSE) 218 (94.8) 2 (0.9) 10 (4.3) 0
Someone who has had HPV vaccine cannot develop cervical cancer (FALSE) 205 (90.3) 8 (3.5) 14 (6.2) 3
The recommended number of HPV vaccine doses is three34 (TRUE) 202 (88.2) 7 (3.1) 20 (8.7) 1
The HPV vaccines are most effective if given to people who have never had sex (TRUE) 189 (82.5) 25 (10.9) 15 (6.6) 1
The HPV vaccines offer protection against most cervical cancers (TRUE) 185 (81.1) 29 (12.7) 14 (6.1) 2
The HPV vaccine offers protection against genital warts (TRUE) 156 (68.1) 41 (17.9) 32 (14.0) 1
1Omitted from % calculations
2Question from Waller et al [12] and in addition to Patel et al [11]
3Wording altered from Patel et al [11] for New Zealand context
4A two-dose schedule for individuals aged 14 and under was implemented in January 2017 so it is possible that some of the No/Don’t know responses reflected this fact.
https://doi.org/10.1371/journal.pone.0197648.t002
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The following questions were answered incorrectly most often: The HPV vaccine offers
protection against genital warts (31.9% answered incorrectly or weren’t sure); The HPV
vaccines offer protection against most cervical cancers (18.8%); The HPV vaccines are most
effective if given to people who have never had sex (17.5%). In addition, more than 10% of par-
ticipants incorrectly thought (or weren’t sure) that the recommended number of HPV vaccine
doses was not three.
Factors influencing level of HPV knowledge
Table 3 shows the effect of predictors on the three types of knowledge, both unadjusted
(‘crude’) and adjusted for the other covariates (‘full model’). Having ever taken a smear was
significantly positively associated with all three types of knowledge when entered into the
model as the only predictor. However, when adjusting for the other predictors, the association
with having ever taken a smear was attenuated for all knowledge types and only remained sig-
nificantly associated with Triage and TOC knowledge score (where those who had ever taken a
smear were more likely to have a higher knowledge score than those who had not taken a
smear (OR 3.59, 95% CI 1.81–7.10, p< 0.01).
Years since HPV training was also associated with knowledge level in univariate analysis,
where those who had had training (either� 1 year ago or> 1 year ago) were more likely to
have a higher knowledge score than those who had never had HPV training, across all types of
knowledge. The association was more pronounced for those who had had more recent training
(� 1 year ago) than for those who had training longer ago (> 1 year ago) for two out of the
three domains, as expected. The association was attenuated when taking into other predictors
on knowledge. However, having had HPV training� 1 year ago compared to never remained
significantly independently predictive of HPV knowledge score and Triage and TOC knowl-
edge score; having had training > 1 year ago compared to never also remained significantly
independently predictive of Triage and TOC knowledge score. Years since training was not
predictive of HPV vaccine knowledge score after adjustment for the other predictors.
Current role was not associated with HPV knowledge score in univariate or multivariate
analyses. However, current role was associated with the Triage and TOC knowledge score in
univariate analysis with those who worked in colposcopy having a higher knowledge score
than nurses (OR 7.89, 95% CI 1.19–52.19, p = 0.03). This association was attenuated and no
longer statistically significant after adjustment for the other predictors (OR 6.20, 95% CI 0.91–
42.30, p = 0.06). The number of colposcopy workers was very small (n = 4) and comprised 2
individuals who identified themselves as colposcopists and 2 who identified themselves as
colposcopy nurses, so this result should be interpreted with caution. Those that were classed as
laboratory staff or other were less likely to have higher Triage and TOC knowledge scores in
the univariate analyses (OR 0.42, 95% CI 0.23–0.75, p<0.01, but this association disappeared
after adjustment for the other predictors (OR 0.92, 95% CI 0.47–1.81, p = 0.82. The laboratory
staff and other group were also more likely to have lower HPV vaccine knowledge scores than
nurses in both univariate (OR 0.27, 95% CI 0.15–0.48, p< 0.01) and multivariate (OR 0.34,
95% CI 0.17–0.67, p< 0.01) models.
The effect of age on knowledge score was explored in univariate analysis as a potential pre-
dictor, but was not associated with scores for any of the three knowledge types (data not
shown), so was not included in the multivariate analysis.
Attitudes towards HPV vaccine
Of all respondents, 96.5% (N = 220) agreed or strongly agreed that they would recommend the
HPV vaccine (Table 4), with a further 3.5% (N = 8) undecided (there were 2 blank responses).
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Table 3. Ordinal regression of predictors of knowledge.
HPV knowledge score
Crude Full model
OR 95% CI p OR 95% CI p
Ever taken smear
No Ref Ref
Yes 2.51 1.52–4.15 <0.01 1.69 0.83–3.43 0.15
Years since HPV training
Never Ref Ref
�1 year ago 2.85 1.44–5.63 <0.01 2.30 1.04–5.10 0.04
>1 year ago 2.27 1.25–4.14 <0.01 1.76 0.83–3.74 0.14
Current role
Nurse Ref Ref
GP 2.17 0.69–6.82 0.19 2.40 0.69–8.34 0.17
Colposcopy 1.43 0.18–11.42 0.74 1.09 0.13–8.96 0.94
Laboratory staff and other 0.64 0.35–1.16 0.14 1.08 0.54–2.15 0.83
Triage and TOC knowledge score
Crude Full model
OR 95% CI p OR 95% CI p
Ever taken smear
No Ref Ref
Yes 5.33 3.17–8.98 <0.01 3.59 1.81–7.10 <0.01
Years since HPV training
Never Ref Ref
�1 year ago 4.96 2.51–9.81 <0.01 2.59 1.22–5.52 0.01
>1 year ago 5.52 2.97–10.24 <0.01 2.41 1.18–4.95 0.02
Current role
Nurse Ref Ref
GP 0.93 0.32–2.77 0.90 0.89 0.27–2.89 0.84
Colposcopy 7.89 1.19–52.19 0.03 6.20 0.91–42.30 0.06
Laboratory staff and other 0.42 0.23–0.75 <0.01 0.92 0.47–1.81 0.82
HPV vaccine knowledge score
Crude Full model
OR 95% CI p OR 95% CI p
Ever taken smear
No Ref Ref
Yes 2.55 1.55–4.20 <0.01 1.85 0.92–3.73 0.09
Years since HPV training
Never Ref Ref
�1 year ago 2.94 1.46–5.93 <0.01 1.77 0.79–3.94 0.16
>1 year ago 1.92 1.06–3.47 0.03 0.90 0.42–1.91 0.77
Current role
Nurse Ref Ref
GP 0.47 0.16–1.36 0.16 0.46 0.14–1.52 0.21
Colposcopy 1.18 0.17–8.23 0.87 0.99 0.14–7.15 1.00
Laboratory staff and other 0.27 0.15–0.48 <0.01 0.34 0.17–0.67 <0.01
https://doi.org/10.1371/journal.pone.0197648.t003
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In total, 94.3% (N = 215) respondents agreed or strongly agreed that men/boys should be
offered the vaccine (Table 4), with 5.3% (N = 12) undecided and 0.4% (N = 1) in disagreement
(there were 2 blank responses).
Self-perceived adequacy of HPV knowledge
Only 63.7% (N = 144) respondents agreed or strongly agreed that they were adequately
informed about HPV (see Table 4), 23.0% (N = 52) were undecided, while 13.2% (N = 30) dis-
agreed or strongly disagreed (there were 4 blank responses).
Despite this, 73.3% (N = 165) respondents agreed or strongly agreed that they could confi-
dently answer HPV related questions asked by patients (see Table 4). A further 18.2% (N = 41)
were undecided and 8.5% (N = 19) disagreed or strongly disagreed (there were 5 blank
responses).
Independent t-tests confirmed that the knowledge scores for general HPV knowledge, tri-
age and test of cure knowledge and HPV vaccine knowledge were all significantly higher for
those participants who felt they were adequately informed than in those who did not feel they
were or who were unsure (p<0.01). The same was found for the question about feeling confi-
dent in answering patient questions.
Feeling adequately informed and feeling confident in answering patient questions were
both related to having ever taken a smear, years since training, and to a much lesser extent,
current role (data not shown). Therefore, the relationship between self-perceived adequacy
and knowledge was explored further in multivariate analysis using binary logistic regression
(Table 5).
Table 4. Attitudes and adequacy questions.
Response N (%)
Strongly agree Agree Undecided Disagree Strongly disagree Blank1
Would you recommend the HPV vaccine? 179 (78.5) 41 (18.0) 8 (3.5) 0 0 2
Do you think that the vaccine should be offered to men/boys as well? 168 (73.7) 47 (20.6) 12 (5.3) 1 (0.4) 0 2
Do you feel adequately informed about HPV? 30 (13.3) 114 (50.4) 52 (23.0) 27 (11.9) 3 (1.3) 4
Are you able to confidently answer HPV related questions asked by patients? 37 (16.4) 128 (56.9) 41 (18.2) 15 (6.7) 4 (1.8) 5
1Omitted from % calculation
https://doi.org/10.1371/journal.pone.0197648.t004
Table 5. Logistic regression of the effect of knowledge on feeling adequately informed / confident in answering patient questions.
Feeling adequately informed
Crude Adjusted for ever taken a smear, years since training and
current role
OR 95% CI p OR 95% CI p
HPV knowledge 1.34 1.11–1.61 <0.01 1.14 0.93–1.39 0.22
Triage and TOC knowledge 1.30 1.12–1.52 <0.01 1.07 0.89–1.29 0.48
HPV vaccine knowledge 1.66 1.29–2.14 <0.01 1.65 1.21–2.24 <0.01
Feeling confident in answering patient questions
Crude Adjusted for ever taken a smear, years since training and
current role
OR 95% CI p OR 95% CI p
HPV knowledge 1.48 1.22–1.79 <0.01 1.22 0.98–1.52 0.08
Triage and TOC knowledge 1.62 1.36–1.94 <0.01 1.24 1.00–1.53 0.05
HPV vaccine knowledge 2.10 1.60–2.78 <0.01 2.16 1.47–3.17 <0.01
https://doi.org/10.1371/journal.pone.0197648.t005
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Feeling adequately informed and confident in answering patient questions were indepen-
dently predicted by HPV vaccine knowledge after adjustment for the other predictors, while
the associations with HPV knowledge and Triage and TOC knowledge disappeared after
adjustment. Again, the number of health professionals in the colposcopy role category was
very small, so these results should be interpreted with caution.
Improving training
Suggestions for how training might be improved were provided by 36 respondents (15.7%).
They wanted regular updates, more training sessions and several health professionals felt that
online training and other online resources such as research, frequently asked questions and
updates would be useful. A request for specific advice that should be provided to parents and
simple information sheets for both primary care and patients was suggested. There were also
requests to widen the provision of training beyond practice nurses to all healthcare providers,
specifically including GPs, independent vaccinators and Public Health Nurses delivering the
School Based Immunisation programme.
Discussion
Although mean knowledge levels for HPV and the HPV vaccine were reasonable (with each
subset of questions yielding a mean percentage correct score of between 88% and 85%, respec-
tively), only 25.2% and 44.3% of health professionals scored 100% in each category, respec-
tively. Research has been conducted in other countries with HPV vaccination programmes to
explore health professional knowledge about HPV and the vaccination (e.g., [11, 13, 14]).
These studies reveal that, consistent with our NZ results, health professional knowledge about
HPV and the HPV vaccination is frequently incomplete.
An evaluation of knowledge about HPV and HPV vaccination for GP practice nurses in
Leicestershire in the UK, where the vaccination has been administered through the NHS since
2008, found that although general HPV knowledge scores were quite high, there were specific
gaps or weaknesses in knowledge [11] for example nearly 10% of PNs did not know that HPV
causes cervical cancer and 63% believed that HPV requires treatment. Our study also revealed
significant gaps in knowledge. For example, while general HPV knowledge was high, around a
quarter of respondents were unaware that having sex at an early age increases the risk of get-
ting HPV. A quarter of respondents were also unaware that HPV is so common that most sex-
ually active people will be exposed to it in their lifetime. Research has shown that considerable
stigma can be attached to a positive HPV test [15, 16] and that a lower level of education can
be associated with an increase in the negative emotions and stigma that patients experience
[16]. Therefore, it is vital that clinical staff are aware of the widespread nature of the virus so
that they can reassure patients and reduce stigma. A third of participants did not know or were
unclear that HPV does not usually need treatment. This lack of knowledge has the potential to
spread misinformation and cause confusion among patients as they seek treatment that is not
available. Perhaps most worryingly, 13% of respondents either believed that HPV causes HIV/
AIDS or were unclear that it did not.
Other research has demonstrated a lack of complete knowledge about HPV and the HPV
vaccine among health professionals. Nilsen et al explored knowledge of and attitudes to HPV
infection and vaccination among public health nurses and GPS in Northern Norway in 2010,
one year after the HPV vaccination was introduced for 12 year-old girls in Norway [13].
Knowledge of HPV infection, vaccine and cervical cancer was measured with 7 open-ended
questions (e.g. what is the lifetime risk of a sexually active person getting HPV?). The percent-
age of GPs getting each question correct ranged from 26–55% while for the nurses it was 35–
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86%. Self-reported knowledge was considerably higher than actual knowledge. Only 47% of
respondents knew that HPV infection is a necessary cause of cervical cancer.
In Malaysia there has been a school-based HPV vaccination programme since 2010. Jeya-
chelvi et al conducted a survey to explore HPV and HPV vaccination knowledge and attitudes
in primary health clinic nurses who run the vaccination program in Kelantan, Malaysia [14].
Nurses were given 11 questions to assess their knowledge. The mean score was 5.37 with the
minimum score being 0 and the maximum being 9. No question was answered correctly by
more than 87.3% of respondents and the poorest question (External anogenital warts increase
the risk of cancer at the same site where the warts are located. True/False) was answered cor-
rectly by only 10.6%.
Rutten et al conducted a survey exploring clinician knowledge, clinician barriers and per-
ceived parental barriers to HPV vaccination in Rochester US [17]. They found that greater
knowledge of HPV and the HPV vaccination (assessed together using an 11-item scale) was
associated with higher rates of HPV vaccination initiation and completion of the 3-dose vacci-
nation schedule, suggesting that knowledge is important in order to effectively promote HPV
vaccination in addition to reducing stigmatising attitudes of clinicians identified in past
research [18] and discussed in more detail below.
Knowledge about triage and test of cure in our study was lower than for HPV and HPV vac-
cine knowledge (mean percentage correct score of 74%) and only 9.1% of health professionals
correctly answered all the answers in this section. The Leicester UK study discussed above also
revealed gaps in the practice nurse knowledge about current NHS processes around HPV tri-
age and test of cure [11]. For example, the role of HPV testing post-treatment (TOC) was mis-
interpreted, with only 66% acknowledging that all normal, borderline nuclear and mildly
dyskaryotic samples are tested for high risk HPV post-treatment. Not all nurses felt adequately
informed about HPV and a need to improve the provision of training was identified. For the
triage and test of cure questions, while some questions were generally answered accurately in
our study, some questions revealed uncertainty and a lack of understanding of the current
guidelines. For example, fewer than half of the respondents knew that not all cervical samples
showing mild cellular changes are tested for high-risk HPV (only those for women aged 30
and older are tested for HPV under the current NZ guidelines). In addition, almost a quarter
of respondents did not know or were unsure that a negative HPV test means that a woman is
at low risk from cervical cancer. This uncertainty is likely to be problematic when primary
HPV testing is rolled out. Unlike the cell changes that are screened for currently, primary HPV
screening is about identifying a woman’s risk factors. Health professionals will need to be con-
fident in talking with women about what their positive test result means. The test of cure ques-
tions were also correctly answered by fewer than three quarters of the respondents.
In addition to knowledge, other studies have been conducted exploring health profession-
als’ attitudes towards the HPV vaccine. In Italy, almost all of the primary care paediatricians
surveyed believed the vaccine was effective in preventing HPV related diseases in boys (92.3%)
and girls (97.9%) and they also believed it was safe. Despite this only 18.4% always recom-
mended the HPV vaccine to boys aged 11–12 compared with 77.4% who always recommended
it to girls aged 11–12 [19]. In a French survey, 72.4% of general practitioners indicated that
they always or often recommended the vaccine to girls aged 11–14 [20], while in a US survey,
60% of paediatricians and 59% of family doctors recommended the vaccine to girls aged 11–12
compared with 52% and 41% who recommended it to boys aged 11–12 [21]. By contrast in
our survey, the vast majority of health professionals indicated that they would recommend the
vaccine and they also favoured vaccinating boys and men, with only one individual indicating
they would not recommend vaccinating boys and men. This is particularly reassuring since
NZ made the vaccine available to boys from January 2017.
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The public and HPV
The public is generally not well informed about HPV and its health sequelae, even in countries
with well-established vaccine and screening programmes, and the role of health professionals
is vital in mitigating this lack of knowledge [22, 23]. For example, in a survey of 200 NZ univer-
sity health science students (mean age 19.8 years), 50.8% were both unaware of the sexual
transmission of HPV and unwilling to accept a free HPV vaccine, highlighting the need for
education in this age group [24]. In the UK, Sherman and Nailer found that only half of
parents of teenage boys in their survey had heard of HPV and the HPV vaccine, despite the
vaccine having been available to girls in the UK since 2008 [25]. The HPV vaccination pro-
gramme in the UK is school-based and Boyce and Holmes identified that the school nurse
played a vital role in reducing health inequalities associated with vaccine uptake [26]. In
another survey, of young adults exploring psychological traits and vaccine uptake in the US,
Scherer et al suggested that women who receive the HPV vaccine may do so based on informa-
tional evidence and that for both males and females, information about the vaccine “should be
communicated in a way that highlights the risks associated with HPV and reduces uncertainty
about the HPV vaccine” [27].
HPV-related knowledge or lack thereof can also impact cervical screening engagement. A
survey of adult women in Kenya from HIV-1-discordant couples, found that those women
who had never attended screening reported not knowing what a Pap smear was or why they
needed one. After adjusting for age, both education and knowledge of HPV were associated
with ever having a smear test [28]. In a survey of women who underwent first time treatment
for high grade cervical intraepithelial neoplasia (CIN) in Sweden, knowledge about HPV, CIN
and cervical cancer predicted their understanding of their personal risk of cervical cancer [29]
and Barnoy et al have previously identified that lower unrealistic optimism about risk was
associated with intention to undergo screening tests [30]. Crucially, more than two thirds of
the Swedish women surveyed stated they would like “to receive more information about HPV,
cervical cancer and its prevention from health professionals (midwives, gynaecologists, pri-
mary care physicians)” [29]. Furthermore, there is considerable stigma associated with a diag-
nosis of HPV [15, 16]. For example, in a qualitative study, McCaffrey et al., found that HPV
positive women [15] reported levels of stigma and anxiety suggesting that “testing positive for
HPV was associated with adverse social and psychological consequences that were beyond
those experienced by an abnormal smear alone” (p173). Daley et al., found that younger age
and less education were associated with more negative emotions (e.g., anger, shock and worry)
and stigma beliefs (e.g., feeling ashamed, guilty and unclean) in HPV positive women [16]. In
addition, a survey of Hong Kong Chinese healthcare providers exploring levels of knowledge
about HPV and attitudes revealed that more knowledge about HPV predicted less stigmatising
attitudes from healthcare providers [18].
The findings above underscore the need for health professionals to be well informed about
HPV, the vaccine and screening programme.
Health professional education needed
Our results suggest that education about HPV and particularly the use of HPV testing in the
screening programme and test of cure process is urgently needed to address some worrying
gaps in knowledge. This is especially important since further changes to the screening pro-
gramme are due to be implemented, with draft primary HPV screening guidelines recently out
for consultation [31]. As other countries also start to roll out primary HPV screening, the suc-
cess of primary screening engagement in NZ and the rest of the world may well rest upon the
level of knowledge of those health professionals responsible for implementing it.
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The need for education indicated by the knowledge scores was further reinforced by the
fact that over a third of respondents did not agree that they felt adequately informed about
HPV and that being adequately informed and feeling confident in responding to patients’
questions were both associated with knowledge. Suggestions for training were proposed by
some of the respondents. One promising suggestion, which was also proposed by UK practice
nurses [11], was for online training. This would provide a low-cost way to update changes to
the vaccination and/or screening programmes and guidelines in a format that would be easily
accessible to many staff whilst requiring relatively little time commitment to complete. HPV
vaccination online training was developed by the Immunisation Advisory Committee (IMAC)
and was released in August 2017 [32]. This may address some of the knowledge issues associ-
ated with vaccination identified in this study, but additional online training regarding screen-
ing and test of cure is needed.
Limitations
There are several limitations to our study. Firstly, due to the opportunistic recruitment
approach, involving self-selection of study participants, the response rate is unknown. As a
consequence, we were not able to examine whether, and to what extent, bias due to non-
response (or participation bias) has occurred, as we were unable to assess the level of HPV
knowledge in non-responders. Also, as is common for most questionnaire surveys, we cannot
exclude social desirability bias (the tendency of survey respondents to answer questions in a
manner that will be viewed favourably by others), but believe that this type of bias is less likely
to be a significant factor for health professionals. Secondly, the sample is not evenly distrib-
uted across the categories of health professionals, with significantly more nurses having com-
pleted the survey than GPs, colposcopists or laboratory and other staff. Since there are
currently no official data available on the cervical screening workforce in New Zealand, we
are unable to indicate how representative our sample is of that wider group. Thirdly, some of
the questions, such as whether participants felt they could confidently answer HPV related
questions asked by patients, are less relevant to laboratory staff who are less likely to interact
with patients. Lastly, as with all such surveys, by providing questions with true/false/don’t
know response options, the questions themselves might act as a prompt enabling educated
guesses rather than measuring knowledge directly and thus might potentially overestimate
knowledge.
Concluding comments
Our survey is the first to be conducted in NZ that explores health professional knowledge and
understanding about HPV, the vaccine and the role of HPV testing in the cervical screening
programme and it contributes to the international picture about HPV knowledge that is
emerging. It is evident from our findings and those from other countries, that more education
is required to ensure that misinformation, the stigma associated with the sexually transmitted
nature of HPV and widening inequalities do not inadvertently result from interactions
between health professionals and the public.
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